Pfizer
We're Hiring!
Pfizer Innovation & Technology Culture
Pfizer Employee Perspectives
Pfizer’s approach to oncology innovation brings together advanced science, artificial intelligence, machine learning, and cross-functional expertise to accelerate progress in cancer research. Employees describe the work as highly collaborative and multidisciplinary, combining the strengths of researchers, clinicians, data scientists, technologists, and AI experts to make faster, bigger strides in understanding and treating cancer.
“It’s a multi-disciplinary approach that allows us to integrate cutting-edge technologies like AI and machine learning into our research processes, enabling us to make faster and bigger strides in understanding and treating cancer.”
Pfizer Employee Reviews
What People Are Saying About Pfizer
-
Product Innovation: Recent records of NME approvals and first-in-class launches (e.g., U.S. approvals of Beqvez gene therapy and Hympavzi) highlight visible output across modalities. The Seagen acquisition further expands novel oncology formats like ADCs and late-stage assets.
-
Investment in R&D: Company guidance and filings show sustained double‑digit‑billion annual R&D investment (roughly $10.7–$11.7B for 2025). This consistent funding underpins a 100+ program pipeline spanning oncology, vaccines, inflammation, and internal medicine.
-
Emerging Technology Adoption: Company KPIs note faster cycle times (around 5.1 years from first‑in‑human to approval in 2023) alongside a scale‑up of large‑scale digital solutions across R&D and manufacturing. These signals point to systematic use of AI/digital to accelerate development and operations.
Pfizer's Tech Stack
Angular
FRAMEWORKS
AWS (Amazon Web Services)
SERVICES
GitHub
SERVICES
GitLab
SERVICES
Ionic
FRAMEWORKS
Java
LANGUAGES
Kotlin
LANGUAGES
Laravel
FRAMEWORKS
Node.js
FRAMEWORKS
PostgreSQL
DATABASES
Python
LANGUAGES
Swift
LANGUAGES
TypeScript
LANGUAGES
Vue.js
FRAMEWORKS
